STOCK TITAN

[Form 4] BRISTOL MYERS SQUIBB CO Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Cari Gallman, Executive Vice President and General Counsel at Bristol-Myers Squibb Company (BMY), reported a set of insider transactions on 10/02/2025. The filing shows 4,558 restricted stock units (RSUs) treated as acquired under rule code M and converted to shares upon vesting; those RSUs convert one-for-one into common stock when vested. The filing also discloses the disposition of 2,332 shares withheld to cover taxes on the award at an average price of $45.73. After these transactions, Ms. Gallman beneficially owns 11,066 shares of common stock.

The RSUs vest in three equal installments beginning on 10/02/2024, and the reported transactions reflect routine compensation vesting and tax-withholding actions rather than open-market purchases.

Cari Gallman, Vicepresidente Esecutivo e Direttore Generale di Bristol-Myers Squibb Company (BMY), ha riportato una serie di operazioni riservate da insider il 10/02/2025. Il filing mostra 4.558 unità di stock con restrizioni (RSU) considerate acquisite ai sensi del codice di regola M e convertite in azioni al vesting; tali RSU si convertono una per una in azioni ordinarie quando vestono. Il filing segnala anche la disposizione di 2.332 azioni trattenute per coprire le tasse sull’assegnazione a un prezzo medio di $45.73. Dopo queste operazioni, la Signora Gallman detiene beneficiariamente 11.066 azioni di azioni ordinarie.

Le RSU vestono in tre rate uguali a partire dal 10/02/2024, e le operazioni riportate riflettono azioni di vesting di compenso di routine e azioni di ritenuta fiscale anziché acquisti sul mercato aperto.

Cara Gallman, Vicepresidenta Ejecutiva y Asesora General en Bristol-Myers Squibb Company (BMY), informó sobre un conjunto de transacciones de insider el 10/02/2025. El registro muestra 4.558 unidades de acciones restringidas (RSU) tratadas como adquiridas bajo el código de regla M y convertidas en acciones al vesting; esas RSU se convierten uno a uno en acciones ordinarias cuando vencen.

El registro también divulga la disposición de 2.332 acciones retenidas para cubrir impuestos sobre la adjudicación a un precio medio de $45.73. Después de estas transacciones, la Sra. Gallman posee beneficiosamente 11.066 acciones de acciones ordinarias.

Las RSU vencen en tres entregas iguales que comienzan el 10/02/2024, y las transacciones reportadas reflejan acciones de vesting de compensación de rutina y retención de impuestos, más que compras en el mercado abierto.

캐리 갤먼(Cari Gallman), Bristol-Myers Squibb Company(BMY)에서 부사장 겸 일반고문10/02/2025에 내부자 거래 세트를 보고했습니다. 제출서는 4,558개 제한 주식단위(RSU)가 규칙 코드 M에 따라 취득된 것으로 취급되고 베스팅 시 주식으로 1대1로 전환된다고 명시합니다; 이 RSU는 베스팅될 때 1주 1주로 일반 주식으로 전환됩니다. 제출서는 또한 보상에 대한 세금을 충당하기 위해 2,332주가 보유되었음을 공개하며 평균 가격은 $45.73입니다. 이러한 거래 후, Gallman 여사는 일반 주식 11,066주의 유익한 소유를 유지합니다.

RSU는 2024/02/10를 시작으로 같은 비율로 세 번의 분기로 베스팅되며, 보고된 거래는 통상적인 보상 베스팅 및 세금 원천징수 조치를 반영할 뿐이며 공개시장 매매는 아닙니다.

Cari Gallman, Vice-présidente exécutive et conseillère générale chez Bristol-Myers Squibb Company (BMY), a signalé un ensemble de transactions d’initié le 10/02/2025. Le dépôt montre 4 558 unités d’actions restreintes (RSU) traitées comme acquises en vertu du code de règle M et converties en actions au moment de la vesting; ces RSU se convertissent une pour une en actions ordinaires lors de la vesting. Le dépôt divulge également la cession de 2 332 actions retenues pour couvrir les impôts sur l’attribution à un prix moyen de $45.73. Après ces transactions, Mme Gallman détient bénéficiairement 11 066 actions ordinaires.

Les RSU vestent en trois versements égaux à partir du 10/02/2024, et les transactions reportées reflètent des vesting de compensation de routine et des actions de retenue d’impôt plutôt que des achats sur le marché.

Cari Gallman, Executive Vice President und General Counsel bei Bristol-Myers Squibb Company (BMY), berichtete am 10/02/2025 über eine Reihe von Insider-Transaktionen. Die Einreichung zeigt 4.558 Restricted Stock Units (RSUs), die gemäß dem Regelcode M als erworben behandelt und bei Vesting in Aktien umgewandelt werden; diese RSUs wandeln sich eins zu eins in Stammaktien um, wenn sie vesten. Die Einreichung weist außerdem die Veräußerung von 2.332 Aktien aus, die zur Deckung von Steuern auf die Zuteilung bei einem Durchschnittspreis von $45.73 einbehalten wurden. Nach diesen Transaktionen besitzt Frau Gallman vorteilhaft 11.066 Aktien Stammaktien.

Die RSUs vesten in drei gleichen Raten, beginnend am 10/02/2024, und die gemeldeten Transaktionen spiegeln routinemäßige Vesting- und Steuerabzugsmaßnahmen wider und keine Öffentkauf auf dem Markt.

CFari Gallman، نائبة الرئيس التنفيذي والمستشارة العامة في شركة بريستول-مايرز سكويب (BMY)، قد أبلغت عن مجموعة من المعاملات الداخلية في 10/02/2025. يظهر الملف 4,558 وحدة أسهم مقيدة (RSUs) معاملة كمكتسبة وفق رمز القاعدة M وتحول إلى أسهم عند الاستحقاق؛ تتحول تلك RSUs عمودياً واحدًا لواحد إلى الأسهم العادية عند الاستحقاق. كما يكشف الملف عن التصرف في 2,332 سهماً احتُجزت لتغطية الضرائب على الجائزة عند سعر متوسط قدره $45.73. بعد هذه المعاملات، تملك السيدة Gallman بشكل مستفيد 11,066 سهماً من الأسهم العادية.

تستحق RSUs على ثلاث دفعات متساوية تبدأ في 10/02/2024، وتُظهر المعاملات المبلّغ عنها Vesting كنشاطات تعويض روتينية وخصم ضريبي وليس شراء في السوق المفتوحة.

Cari Gallman, 执行副总裁兼首席法务官,任职于 Bristol-Myers Squibb Company(BMY),在 10/02/2025 报告了一系列内幕交易。 文件显示 4,558 受限股票单位(RSUs) 根据规则代码 M 被视为已取得,并在归属时转换为股票;这些 RSUs 在归属时一对一转换为普通股。 文件还披露为覆盖奖励税款而扣留的 2,332 股,其平均价格为 $45.73。 交易完成后,Gallman 女士实际持有 11,066 股 普通股。

这些 RSU 将在三次等额分期归属,首次自 10/02/2024 开始,所报告的交易反映的是常规薪酬归属和税款代扣行为,而非公开市场购买。

Positive
  • 4,558 RSUs vested, converting one-for-one into common shares which increases beneficial ownership
  • Transactions reflect routine compensation settlement and tax withholding, indicating standard administration rather than opportunistic trading
Negative
  • 2,332 shares withheld to pay taxes at an average price of $45.73, reducing net new shares received
  • Net beneficial ownership decreased from the gross vested amount to 11,066 shares after withholding

Insights

Routine executive compensation vesting and tax-withholding activity, not a new policy change.

The report documents the vesting conversion of 4,558 RSUs into common shares and the withholding of 2,332 shares to satisfy tax obligations at an average price of $45.73. This pattern is consistent with standard equity compensation administration following vest dates.

Key dependencies include the remaining vesting schedule (three equal installments starting 10/02/2024) and future withholding events tied to subsequent vesting dates; investors may note these are mechanical transactions with near-term liquidity impact on the reporting person's holdings.

The transaction reduces outstanding personal share count modestly via tax withholding while adding vested shares to beneficial ownership.

The conversion of RSUs into shares increases beneficial ownership by the gross vested amount, but withholding of 2,332 shares lowers net received shares; the form reports 11,066 shares owned after the transactions. The listed acquisition code M and disposition code F reflect administrative settlement and tax withholding, not open-market trading for cash proceeds beyond tax obligations.

Watch the remaining vest schedule for additional tax-withholding events occurring on subsequent vest dates through the vesting term, which will affect future reported beneficial ownership.

Cari Gallman, Vicepresidente Esecutivo e Direttore Generale di Bristol-Myers Squibb Company (BMY), ha riportato una serie di operazioni riservate da insider il 10/02/2025. Il filing mostra 4.558 unità di stock con restrizioni (RSU) considerate acquisite ai sensi del codice di regola M e convertite in azioni al vesting; tali RSU si convertono una per una in azioni ordinarie quando vestono. Il filing segnala anche la disposizione di 2.332 azioni trattenute per coprire le tasse sull’assegnazione a un prezzo medio di $45.73. Dopo queste operazioni, la Signora Gallman detiene beneficiariamente 11.066 azioni di azioni ordinarie.

Le RSU vestono in tre rate uguali a partire dal 10/02/2024, e le operazioni riportate riflettono azioni di vesting di compenso di routine e azioni di ritenuta fiscale anziché acquisti sul mercato aperto.

Cara Gallman, Vicepresidenta Ejecutiva y Asesora General en Bristol-Myers Squibb Company (BMY), informó sobre un conjunto de transacciones de insider el 10/02/2025. El registro muestra 4.558 unidades de acciones restringidas (RSU) tratadas como adquiridas bajo el código de regla M y convertidas en acciones al vesting; esas RSU se convierten uno a uno en acciones ordinarias cuando vencen.

El registro también divulga la disposición de 2.332 acciones retenidas para cubrir impuestos sobre la adjudicación a un precio medio de $45.73. Después de estas transacciones, la Sra. Gallman posee beneficiosamente 11.066 acciones de acciones ordinarias.

Las RSU vencen en tres entregas iguales que comienzan el 10/02/2024, y las transacciones reportadas reflejan acciones de vesting de compensación de rutina y retención de impuestos, más que compras en el mercado abierto.

캐리 갤먼(Cari Gallman), Bristol-Myers Squibb Company(BMY)에서 부사장 겸 일반고문10/02/2025에 내부자 거래 세트를 보고했습니다. 제출서는 4,558개 제한 주식단위(RSU)가 규칙 코드 M에 따라 취득된 것으로 취급되고 베스팅 시 주식으로 1대1로 전환된다고 명시합니다; 이 RSU는 베스팅될 때 1주 1주로 일반 주식으로 전환됩니다. 제출서는 또한 보상에 대한 세금을 충당하기 위해 2,332주가 보유되었음을 공개하며 평균 가격은 $45.73입니다. 이러한 거래 후, Gallman 여사는 일반 주식 11,066주의 유익한 소유를 유지합니다.

RSU는 2024/02/10를 시작으로 같은 비율로 세 번의 분기로 베스팅되며, 보고된 거래는 통상적인 보상 베스팅 및 세금 원천징수 조치를 반영할 뿐이며 공개시장 매매는 아닙니다.

Cari Gallman, Vice-présidente exécutive et conseillère générale chez Bristol-Myers Squibb Company (BMY), a signalé un ensemble de transactions d’initié le 10/02/2025. Le dépôt montre 4 558 unités d’actions restreintes (RSU) traitées comme acquises en vertu du code de règle M et converties en actions au moment de la vesting; ces RSU se convertissent une pour une en actions ordinaires lors de la vesting. Le dépôt divulge également la cession de 2 332 actions retenues pour couvrir les impôts sur l’attribution à un prix moyen de $45.73. Après ces transactions, Mme Gallman détient bénéficiairement 11 066 actions ordinaires.

Les RSU vestent en trois versements égaux à partir du 10/02/2024, et les transactions reportées reflètent des vesting de compensation de routine et des actions de retenue d’impôt plutôt que des achats sur le marché.

Cari Gallman, Executive Vice President und General Counsel bei Bristol-Myers Squibb Company (BMY), berichtete am 10/02/2025 über eine Reihe von Insider-Transaktionen. Die Einreichung zeigt 4.558 Restricted Stock Units (RSUs), die gemäß dem Regelcode M als erworben behandelt und bei Vesting in Aktien umgewandelt werden; diese RSUs wandeln sich eins zu eins in Stammaktien um, wenn sie vesten. Die Einreichung weist außerdem die Veräußerung von 2.332 Aktien aus, die zur Deckung von Steuern auf die Zuteilung bei einem Durchschnittspreis von $45.73 einbehalten wurden. Nach diesen Transaktionen besitzt Frau Gallman vorteilhaft 11.066 Aktien Stammaktien.

Die RSUs vesten in drei gleichen Raten, beginnend am 10/02/2024, und die gemeldeten Transaktionen spiegeln routinemäßige Vesting- und Steuerabzugsmaßnahmen wider und keine Öffentkauf auf dem Markt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gallman Cari

(Last) (First) (Middle)
BRISTOL-MYERS SQUIBB COMPANY
ROUTE 206 AND PROVINCE LINE ROAD

(Street)
PRINCETON NJ 08543

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.10 par value 10/02/2025 M 4,558(1) A $0 13,398 D
Common Stock, $0.10 par value 10/02/2025 F 2,332(2) D $45.73 11,066 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 10/02/2025 M 4,558 (3) 10/02/2026 Common Stock, $0.10 par value 4,558 $0 4,559 D
Explanation of Responses:
1. The restricted stock units vest in three equal installments beginning on October 2, 2024.
2. Shares withheld for payment of taxes upon vesting of award.
3. Each restricted stock unit converts into one share of common stock upon vesting.
Remarks:
/s/ Sophie M. Bail, attorney-in-fact for Cari Gallman 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Cari Gallman report on Form 4 for BMY?

The filing reports the vesting conversion of 4,558 RSUs and the withholding sale of 2,332 shares to cover taxes at an average price of $45.73 on 10/02/2025.

How many shares does Cari Gallman beneficially own after these transactions (BMY)?

Following the reported transactions, Cari Gallman beneficially owns 11,066 shares of Bristol-Myers Squibb common stock.

Why were shares sold in this Form 4 for BMY?

The filing indicates the disposition of 2,332 shares was for tax withholding upon vesting of an equity award, not an open-market sale for discretionary cash.

When do the RSUs vest for Cari Gallman's award?

The RSUs vest in three equal installments beginning on 10/02/2024, with each RSU converting into one share upon vesting.

What transaction codes appear on the Form 4 (BMY) and what do they mean?

The form uses code M (conversion/settlement upon vesting) for the RSU acquisition and code F for shares withheld to satisfy tax obligations.
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

BMY Latest News

BMY Latest SEC Filings

BMY Stock Data

91.88B
2.03B
0.07%
82.82%
1.53%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON